IRCT20081202001483N4招募中3 期
Comparison of cisplatin otoprotection using intratympanic diltiazem and placebo among patients with solid cancer
Rasht University of Medical Sciences0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Age over 18 years old
- •Presence of Acoustic Reflex or Tympanometry A
- •In PTA, average hearing threshold at frequencies of 3000-5000 or 8000 to 4000 less than 40 dB
- •In PTA, the hearing threshold on either side should not be asymetric within 3000 to 5000 or 8000-4000 Hz frequencies or there is less than 10 dB
- •The karnofsky index is equal to or greater than 70
排除标准
- •History of previous internal ear disease that may reduce the sensory nervous system hearing
- •History of Meniere's disease Or fluticating hearing loss
- •Observing pathologic findings in otoscopy
- •Previously cisplatin has not been treated
- •Radiation History to the head and neck Area
- •Candidate for radiation to the head and neck
- •Liver and Renal failure
- •Conductive hearing loss more than 5 dB
- •Heart problems, such as hypotension or AV block
研究者
相似试验
进行中（未招募）
1 期
A trial to identify if Aspirin can reduce hearing loss for patients receiving Cisplatin chemotherapyEUCTR2012-001509-25-GBniversity Hospital Southampton NHS Foundation Trust94
尚未招募
不适用
Comparative response evaluation of Cisplatin-Capecitabine with Cisplatin-5-Fluorouracil in advanced gastric carcinoma.Clinically diagnosed and histopathologically proved advanced gastric carcinoma (AJCC Stage IV).Advanced gastric carcinoma.TCTR20170715001Bangabandhu Sheikh Mujib Medical University62
已完成
不适用
Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck CancerCisplatin Adverse ReactionHearing Loss OtotoxicNCT03400709Hospital San Juan de Dios, Santiago45
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusEUCTR2019-000308-13-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)180
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusOropharyngeal Squamous Cell CarcinomaMedDRA version: 20.1Level: LLTClassification code 10079785Term: Oropharyngeal squamous cell carcinoma stage IVSystem Organ Class: 100000004864EUCTR2019-000308-13-ITEuropean Organisation for Research and Treatment of Cancer (EORTC)180